IDiyas

For the Inventor, By the Inventor

Oxford, United Kingdom

Oxford Biomedica (uk) Limited


USPTO Granted Patents = 53

Trademarks = 1

Forward Citations = 391

Loading Chart...
Loading Chart...

55 inventors (with patents filed for the assignee):

goldMedal Miles William Carroll (19 out of 19 patents)

silverMedal Kyriacos Andreou Mitrophanous (18 out of 20 patents)

bronzeMedal Alan John Kingsman (17 out of 23 patents)

4.  Susan Mary Kingsman (16 out of 26 patents)

5.  Kevin Alan Myers (13 out of 14 patents)

6.  Fiona Margaret Ellard (9 out of 10 patents)

7.  Susan Marie Kingsman (9 out of 10 patents)

8.  Christopher Robert Bebbington (8 out of 44 patents)

9.  Richard Harrop (5 out of 6 patents)

10.  James Miskin (4 out of 4 patents)

11.  Narry Kim (4 out of 6 patents)

12.  Scott Ralph (3 out of 3 patents)

13.  Hannah Stewart (3 out of 3 patents)

14.  Paula M Cannon (3 out of 6 patents)

15.  Daniel Farley (3 out of 3 patents)


Core Competencies:
Retroviral Vector
Viral Vector Production
5T4-Targeting Agents
Virus Purification
Chemo-Immunotherapy
Antiviral Vectors
Polypeptide
Lentiviral Vectors
Tumor Targeted Vector
Nucleic Acid Constructs
Mononuclear Phagocytes
Equine Infectious Anemia Virus

53 patents:

1. 12312592 - Retroviral vector (2025-05-27),
2. 12054735 - Viral vector production system (2024-08-06),
3. 11427645 - 5T4-targeting agents and methods (2022-08-30),
4. 11279954 - Catecholamine enzyme fusions (2022-03-22),
5. 10544429 - Viral vector production system (2020-01-28),
6. 10400252 - Catecholamine enzyme fusions (2019-09-03),
7. 10273502 - Virus purification (2019-04-30),
8. 9738907 - Viral vector (2017-08-22),
9. 9339512 - Method for vector delivery (2016-05-17),
10. 9169491 - Virus purification (2015-10-27),
11. 8147838 - Peptide (2012-04-03),
12. 8133681 - Chemo-immunotherapy method (2012-03-13),
13. 8084249 - Vector (2011-12-27),
14. 7910109 - MHC class II epitopes of 5T4 antigen (2011-03-22),
15. 7888115 - MHC class I peptide epitopes from the human 5T4 tumor-associated antigen (2011-02-15),
Oxford BioMedica (UK) Limited is a biotechnology company specializing in gene and cell therapy. They develop innovative treatments for serious diseases, including ocular disorders, oncology, and central nervous system disorders. Oxford BioMedica focuses on delivering life-changing gene-based medicines using their proprietary LentiVector® platform. Through collaborations with academic institutions and pharmaceutical partners, they strive to improve patient outcomes and advance the field of gene therapy.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

53 Patents

#8 in Oxford

#322 in United Kingdom

#12,935 in the World

...
Oxford, United Kingdom

Oxford Biomedica (uk) Limited

Forward Citations = 391

55 inventors:

goldMedal Miles William Carroll (19 out of 19 patents)

silverMedal Kyriacos Andreou Mitrophanous (18 out of 20 patents)

bronzeMedal Alan John Kingsman (17 out of 23 patents)

4.  Susan Mary Kingsman (16 out of 26 patents)

5.  Kevin Alan Myers (13 out of 14 patents)

Please report any incorrect information to support@idiyas.com
Loading…